[Multiple sclerosis: current therapies and future perspectives].

研究成果: ジャーナルへの寄稿評論記事

1 引用 (Scopus)

抄録

Multiple sclerosis is characterized by temporal and spatial dissemination of demyelination in the central nervous system. After a discovery of disease modifying effects of interferon beta and glatiramer acetate for multiple sclerosis, many drugs for disease modifying therapy have been developed. Recently, some multicenter studies have shown that early introduction of interferon beta or glatiramer acetate into patients with clinically isolated syndrome delayed the conversion to clinically definite multiple sclerosis. Newly developed disease modifying therapies for multiple sclerosis have a specific molecular target changing an immunological reaction and many of them are oral preparations instead of injectable first line therapies. Treatment options for multiple sclerosis are increasing and it is essential for the optimal treatment choice to collect information of the long-term side effects and the combined effects with first line therapies and to acquire the knowledge of the pathomechanisms about multiple sclerosis.

元の言語英語
ページ(範囲)2077-2086
ページ数10
ジャーナルNihon rinsho. Japanese journal of clinical medicine
69
発行部数11
出版物ステータス出版済み - 1 1 2011

Fingerprint

Multiple Sclerosis
Interferon-beta
Therapeutics
Demyelinating Diseases
Multicenter Studies
Central Nervous System
Injections
Pharmaceutical Preparations
Glatiramer Acetate

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

[Multiple sclerosis : current therapies and future perspectives]. / Matsushita, Takuya.

:: Nihon rinsho. Japanese journal of clinical medicine, 巻 69, 番号 11, 01.01.2011, p. 2077-2086.

研究成果: ジャーナルへの寄稿評論記事

@article{f5212ecc012949e0b831fe0470cebd82,
title = "[Multiple sclerosis: current therapies and future perspectives].",
abstract = "Multiple sclerosis is characterized by temporal and spatial dissemination of demyelination in the central nervous system. After a discovery of disease modifying effects of interferon beta and glatiramer acetate for multiple sclerosis, many drugs for disease modifying therapy have been developed. Recently, some multicenter studies have shown that early introduction of interferon beta or glatiramer acetate into patients with clinically isolated syndrome delayed the conversion to clinically definite multiple sclerosis. Newly developed disease modifying therapies for multiple sclerosis have a specific molecular target changing an immunological reaction and many of them are oral preparations instead of injectable first line therapies. Treatment options for multiple sclerosis are increasing and it is essential for the optimal treatment choice to collect information of the long-term side effects and the combined effects with first line therapies and to acquire the knowledge of the pathomechanisms about multiple sclerosis.",
author = "Takuya Matsushita",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "69",
pages = "2077--2086",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "11",

}

TY - JOUR

T1 - [Multiple sclerosis

T2 - current therapies and future perspectives].

AU - Matsushita, Takuya

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Multiple sclerosis is characterized by temporal and spatial dissemination of demyelination in the central nervous system. After a discovery of disease modifying effects of interferon beta and glatiramer acetate for multiple sclerosis, many drugs for disease modifying therapy have been developed. Recently, some multicenter studies have shown that early introduction of interferon beta or glatiramer acetate into patients with clinically isolated syndrome delayed the conversion to clinically definite multiple sclerosis. Newly developed disease modifying therapies for multiple sclerosis have a specific molecular target changing an immunological reaction and many of them are oral preparations instead of injectable first line therapies. Treatment options for multiple sclerosis are increasing and it is essential for the optimal treatment choice to collect information of the long-term side effects and the combined effects with first line therapies and to acquire the knowledge of the pathomechanisms about multiple sclerosis.

AB - Multiple sclerosis is characterized by temporal and spatial dissemination of demyelination in the central nervous system. After a discovery of disease modifying effects of interferon beta and glatiramer acetate for multiple sclerosis, many drugs for disease modifying therapy have been developed. Recently, some multicenter studies have shown that early introduction of interferon beta or glatiramer acetate into patients with clinically isolated syndrome delayed the conversion to clinically definite multiple sclerosis. Newly developed disease modifying therapies for multiple sclerosis have a specific molecular target changing an immunological reaction and many of them are oral preparations instead of injectable first line therapies. Treatment options for multiple sclerosis are increasing and it is essential for the optimal treatment choice to collect information of the long-term side effects and the combined effects with first line therapies and to acquire the knowledge of the pathomechanisms about multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84855528182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855528182&partnerID=8YFLogxK

M3 - Review article

C2 - 22111333

AN - SCOPUS:84855528182

VL - 69

SP - 2077

EP - 2086

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 11

ER -